Litigation Details for Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc. (D. Del. 2015)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc. (D. Del. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-10-13 |
| Court | District Court, D. Delaware | Date Terminated | 2016-10-27 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | None | Referred To | |
| Patents | 8,586,610; 9,138,432 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc. (D. Del. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2015-10-13 | 1 | or more claims of Vanda’s U.S. Patent No. 8,586,610 (“the ’610 patent”) and Taro’s infringement of claim…c) and 1400(b). IV. THE PATENTS-IN-SUIT – U.S. PATENT NOS. 8,586,610 AND 9,138,432 …claim 1 of Vanda’s U.S. Patent No. 9,138,432 (“the ’432 patent”), which relate to the field of schizophrenia…’610 patent, or any extensions thereof. Taro will infringe one or more claims of the ’610 patent under… the ’432 patent, or any extensions thereof. Taro will infringe claim 1 of the ’432 patent under 35 U.S.C | External link to document | |
| 2015-10-13 | 3 | Notice: N/A. Date of Expiration of Patent: 11/2/2027-U.S. 8,586,610; 9/30/2025-U.S. 9,138,432. Thirty … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2015 27 October 2016 1:15-cv-00920 830 Patent None District Court, D. Delaware | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
